Cerubidine
(Daunorubicin Hydrochloride)Phase 3Small molecule
Daunorubicin is used to treat certain types of cancer, particularly leukemia and lymphoma, by killing cancer cells. It works by damaging cancer cell DNA so the cells cannot survive and spread.[1] Cerubidine is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]
Cerubidine is one of 332 small molecule programs targeting T-cell acute lymphoblastic leukemia. It is currently in Phase 3.
17
Indications
125
Total Trials
19
Active Trials
331
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Stem Cells
KKang Stem Biotech Co., Ltd.
Preclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia43 trials
Show 40 more trials
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
Recruiting·—·Phase 1·NCT05157971·24 enrolled
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Recruiting·—·Phase 2·NCT06918431·53 enrolled
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed·—·Phase 2·NCT00618501·50 enrolled
Acute Myeloid Leukemia41 trials
Show 38 more trials
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Unknown status·IInstitut de Recherche Clinique sur les Cancers et le Sang·Phase 1·NCT00544999·21 enrolled
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004128·2,000 enrolled
Leukemia10 trials
Show 7 more trials
Lymphoma4 trials
14 more indications
Myelodysplastic Syndrome4 trials
Myelodysplastic Syndromes3 trials
Lymphoblastic Lymphoma3 trials
Acute Promyelocytic Leukemia2 trials
B Acute Lymphoblastic Leukemia2 trials
Myeloproliferative Disorder1 trial
T-cell acute lymphoblastic leukemia1 trial
Newly Diagnosed1 trial
Chronic Myelogenous Leukemia1 trial
Core Binding Factor Acute Myeloid Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Daunorubicin Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details